Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals.
Mathieu ChalouniJavier Rodriguez-CentenoAssia SamriJulian BlancoNatalia Stella-AscarizCedrick WalletHernando KnobelDavid ZucmanBelen Alejos FerrerasBrigitte AutranRodolphe ThiebautFrançois RaffiJose Ramon Arribasnull nullPublished in: PloS one (2020)
In 31 participants who started first-line antiretroviral therapy in the NEAT 001/ANRS 143 clinical trial, we found after 96 weeks a statistically significant increase in blood telomere length (TL) of 0.04 (T/S Ratio) (p = 0.03). This increase was positively correlated with both the change in the percentage of CD4+ T-cells and with the decrease of CD38+ molecules on Central Memory CD8+ and negatively correlated with the change in the percentage of CD4+ Effector Memory cells. Increase in TL could be an expression of immune reconstitution and the associated decrease in immune activation. We acknowledge for the low statistical power due to the small sample size and the potential for false positive results due to multiple testing. Hence, further studies are needed to confirm these observations.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- human immunodeficiency virus
- clinical trial
- men who have sex with men
- hiv infected patients
- hiv aids
- south africa
- poor prognosis
- nk cells
- induced apoptosis
- working memory
- cell cycle arrest
- immune response
- risk assessment
- signaling pathway
- cell death
- dendritic cells
- hepatitis c virus
- study protocol
- long non coding rna
- binding protein
- cell proliferation
- phase iii
- case control